| Lillehei, Kevin O |
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM |
|
|
| Recruiting | 3 | 560 | Europe, US | SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal | CarThera | Glioblastoma, Recurrent Glioblastoma, GBM | 01/28 | 06/28 | | |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
| Gonzalez, Rene |
NCT05089370: Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma |
|
|
| Active, not recruiting | 1/2 | 8 | US | Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab | University of Colorado, Denver, National Comprehensive Cancer Network, Taiho Oncology, Inc. | Malignant Melanoma | 07/25 | 07/26 | | |
| Messersmith, Wells |
AGICC, NCT02723331: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates |
|
|
| Active, not recruiting | 2 | 48 | US | Nab paclitaxel, Abraxane, Gemcitabine, Gemzar | Academic Thoracic Oncology Medical Investigators Consortium, Celgene Corporation, Criterium, Inc., University of Colorado, Denver | Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma | 12/22 | 05/25 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 48 | US | Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda | University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC) | Microsatellite Stable Metastatic Colorectal Cancer | 12/25 | 03/26 | | |
| Recruiting | 1 | 345 | Europe, US | NX-1607, Cbl-b Inhibitor, Paclitaxel | Nurix Therapeutics, Inc. | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 08/26 | 02/28 | | |
| Jimeno, Antonio |
| Terminated | 1/2 | 20 | US | SQZ-eAPC-HPV, Pembrolizumab | SQZ Biotechnologies | Adult Solid Tumor | 11/23 | 11/23 | | |
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 125 | US | DSP107, Atezolizumab | Kahr Medical | Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer | 09/25 | 09/25 | | |
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | Canada, US, RoW | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
NCT05053737: Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC |
|
|
| Completed | 1 | 11 | US | Atezolizumab, MPDL3280A, RG7446, Tecentriq, Stereotactic Body Radiation Therapy, SBRT | University of Colorado, Denver, Genentech, Inc. | Squamous Cell Carcinoma of Head and Neck | 11/23 | 06/24 | | |
| Goodman, Karyn A |
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer |
|
|
| Terminated | 2 | 177 | Europe, Canada, US | Drug GC4711, Placebo | Galera Therapeutics, Inc. | SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer | 11/23 | 11/23 | | |
| LeBlanc, Julia |
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles |
|
|
| Recruiting | N/A | 30000 | Europe, Canada, US, RoW | MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint | Agendia | Breast Cancer | 04/37 | 12/37 | | |
| Camidge, David R |
| Active, not recruiting | 2 | 240 | Europe, US, RoW | CAB-AXL-ADC, BA3011, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non-Small-Cell Lung Cancer | 08/25 | 08/25 | | |
NCT04739358: CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC |
|
|
| Terminated | 1/2 | 2 | US | Tepotinib, Tepmetko | Criterium, Inc., EMD Serono Research & Development Institute, Inc. | Advanced Non-Small Cell Lung Cancer With MET Mutations | 06/23 | 06/23 | | |
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients |
|
|
| Active, not recruiting | 1/2 | 85 | US | avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI® | Verastem, Inc., Mirati Therapeutics Inc. | Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease | 12/24 | 01/25 | | |
| Completed | 1/2 | 132 | Europe, US, RoW | CAB-ROR2-ADC, BA3021, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 12/24 | 12/24 | | |
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer |
|
|
| Recruiting | 1/2 | 237 | US | REGN5093-M114, Cemiplimab | Regeneron Pharmaceuticals | Advanced NSCLC | 02/30 | 02/30 | | |
| Gutman, Jonathan A |
| Active, not recruiting | 2 | 30 | Europe, US | ECT-001-CB (UM171-Expanded Cord Blood Transplant) | ExCellThera inc., Fred Hutchinson Cancer Center | High Risk Hematological Malignancy, Cord Blood Transplant | 02/26 | 02/26 | | |
| Recruiting | 2 | 55 | US | Zoster Vaccine Recombinant, Shingrix | University of Colorado, Denver, GlaxoSmithKline | Bone Marrow Transplant, Stem Cell Transplant | 05/25 | 12/30 | | |
| Recruiting | 1 | 35 | US | Venetoclax, ABT-199, Abbvie, CC-486 | University of Colorado, Denver, Bristol-Myers Squibb | AML | 03/27 | 03/29 | | |
| Ney, Douglas |
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response |
|
|
| Terminated | 2 | 32 | US | Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment | OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services | Central Nervous System B-Cell Non-Hodgkin Lymphoma | 03/24 | 03/24 | | |
| Pollyea, Daniel Aaron |
NCT03573024: Venetoclax and Azacitidine for Non-Elderly Adult Patients with Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 2 | 36 | US | Azacitidine, Venetoclax | University of Colorado, Denver, AbbVie | Acute Myeloid Leukemia | 06/26 | 06/27 | | |
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | Cusatuzumab, OV-1001, Venetoclax, Azacitidine | OncoVerity, Inc. | Leukemia, Myeloid, Acute | 01/27 | 06/27 | | |
| Active, not recruiting | 1 | 106 | US | IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven | Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM) | AML With Monocytic Differentiation, CMML | 01/26 | 01/27 | | |
NCT04914845: KPT-9274 in Patients with Relapsed and Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 40 | US | KPT-9274 | University of Colorado, Denver, Karyopharm Therapeutics Inc | Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 02/26 | 02/27 | | |
| Recruiting | 1 | 35 | US | Venetoclax, ABT-199, Abbvie, CC-486 | University of Colorado, Denver, Bristol-Myers Squibb | AML | 03/27 | 03/29 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 470 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) |
|
|
| Not yet recruiting | 1 | 56 | US | SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control | South Rampart Pharma, LLC | Pain | 12/25 | 03/26 | | |
NCT05583669: A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 05/23 | 05/23 | | |
NCT05633745: A Study to Assess NEU-723 in Healthy Participants |
|
|
| Terminated | 1 | 40 | RoW | NEU-723, Placebo | Neuron23 Inc. | Healthy | 06/23 | 06/23 | | |
| Recruiting | 1 | 85 | Europe, US | DS-9606a | Daiichi Sankyo | Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor | 02/26 | 02/26 | | |
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma |
|
|
| Completed | 1 | 10 | RoW | 89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx | Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd. | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | 11/23 | 11/23 | | |
KEYNOTE-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 115 | Europe, US | Trastuzumab deruxtecan (DS-8201a), Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca UK Limited, Merck Sharp & Dohme LLC | Breast Cancer, Non-small Cell Lung Carcinoma | 12/24 | 08/25 | | |
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema |
|
|
| Active, not recruiting | 1 | 42 | US | EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose | Emmecell | Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation | 10/24 | 10/24 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
| Recruiting | 1 | 210 | Japan, US | Valemetostat tosylate, DS-3201b, T-DXd, DS-8201a, ENHERTU, Dato-DXd, DS-1062a | Daiichi Sankyo | Advanced Solid Tumor | 11/28 | 11/28 | | |
NCT05755191: A Study to Assess NEU-411 in Healthy Participants |
|
|
| Completed | 1 | 147 | RoW | NEU-411, Placebo | Neuron23 Inc. | Healthy | 06/24 | 06/24 | | |
NCT05628961: Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics |
|
|
| Recruiting | 1 | 42 | US | HOPO 14-1 | SRI International | Toxicity;Chemical | 04/24 | 04/24 | | |
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 72 | US | BBP-398 (Formerly known as IACS-15509) | Navire Pharma Inc., a BridgeBio company | Tumor, Solid | 03/24 | 07/24 | | |
NCT05940571: First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors |
|
|
| Recruiting | 1 | 41 | Europe | MBF-362 | Medibiofarma S.L. | Cancer | 01/25 | 01/25 | | |
| Recruiting | 1 | 56 | US | THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo | Third Harmonic Bio, Inc. | Healthy | 03/25 | 03/25 | | |
NCT06547554: A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants |
|
|
| Recruiting | 1 | 40 | US | Xeruborbactam, QPX7728, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water | Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority | Bacterial Infections | 12/25 | 12/25 | | |
| Active, not recruiting | 1 | 33 | US | Influenza A/Texas/71/2017 (H3N2), Sham placebo | Duke University, United States Department of Defense, Owlstone Ltd, Darwin Biosciences | Influenza Viral Infections | 02/25 | 04/25 | | |
NCT06500442: A Study to Assess NEU-111 in Healthy Participants |
|
|
| Recruiting | 1 | 64 | RoW | NEU-111, Placebo | Neuron23 Inc. | Healthy | 01/25 | 02/25 | | |
NCT06600607: Pharmacodynamic Study of 300mg Pregabalin Vs Placebo in Healthy Male Adults |
|
|
| Not yet recruiting | 1 | 20 | RoW | pregabalin 300 mg, Placebo | Latigo Biotherapeutics | Pain Detection, Pain Threshold | 10/24 | 10/24 | | |
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors |
|
|
| Active, not recruiting | 1 | 179 | Japan, US | DS-6000a, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Renal Cell Carcinoma, Ovarian Tumor | 04/25 | 11/25 | | |
NCT06579144: Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A |
|
|
| Not yet recruiting | 1 | 24 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio | Swedish Orphan Biovitrum, PSI CRO | Hemophilia A | 03/25 | 04/25 | | |
